Outbreaks of severe virus infections with the potential to cause global pandemics are
increasing. In many instances these outbreaks have been newly emerging (SARS …

The 2014–2015 outbreak of Ebola virus disease is the largest epidemic to date in terms of
the number of cases, deaths, and affected areas. In October 2015, no antiviral agents had …

Without an approved vaccine or treatments, Ebola outbreak management has been limited
to palliative care and barrier methods to prevent transmission. These approaches, however …

Outbreaks of Ebola hemorrhagic fever in sub-Saharan Africa are associated with case
fatality rates of up to 90%. Currently, neither a vaccine nor an effective antiviral treatment is …

The current outbreak of Ebola virus in West Africa is unprecedented, causing more cases
and fatalities than all previous outbreaks combined, and has yet to be controlled. Several …

The genus Ebolavirus from the family Filoviridae is composed of five species including
Sudan ebolavirus, Reston ebolavirus, Bundibugyo ebolavirus, Taï Forest ebolavirus, and …

Background Up to now, all tested Ebola virus vaccines have been based on the virus strain
from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a …

It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV)
vaccines. In the absence of efficacy data, immunobridging is an approach to infer the …

The filoviruses—Ebola virus and Marburg virus—cause lethal haemorrhagic fever in
humans and non-human primates (NHPs). Filoviruses present a global health threat both as …

Ebola virus (EBOV) causes severe hemorrhagic fever for which there is no approved
treatment or preventive vaccine. Immunological correlates of protective immunity against …